Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort Study.
暂无分享,去创建一个
M. Federico | C. Gisselbrecht | S. Horwitz | S. Rosen | E. Hsi | K. Carson | L. Bellm | B. Pro | F. Foss | F. Lansigan | L. Pinter-Brown | A. Shustov | M. Schwartz | M. Acosta
[1] M. Weichenthal,et al. The PROCLIPI international registry of early‐stage mycosis fungoides identifies substantial diagnostic delay in most patients , 2018, The British journal of dermatology.
[2] M. Weichenthal,et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial , 2017, The Lancet.
[3] R. Advani,et al. A prospective cohort study of patients with peripheral T‐cell lymphoma in the United States , 2017, Cancer.
[4] D. Sui,et al. Retrospective Analysis of Prognostic Factors in 187 Cases of Transformed Mycosis Fungoides. , 2016, Clinical lymphoma, myeloma & leukemia.
[5] R. Cowan,et al. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] L. Reiniger,et al. Altered MicroRNA Expression in Folliculotropic and Transformed Mycosis Fungoides , 2015, Pathology & Oncology Research.
[7] E. Chang,et al. Outcomes after diagnosis of mycosis fungoides and Sézary syndrome before 30 years of age: a population-based study. , 2014, JAMA dermatology.
[8] L. Hughey,et al. Large-cell transformation of mycosis fungoides-differential diagnosis with implications for clinical management: a consensus statement of the US Cutaneous Lymphoma Consortium. , 2014, Journal of the American Academy of Dermatology.
[9] B. Coiffier,et al. Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study. , 2012, Clinical lymphoma, myeloma & leukemia.
[10] R. Willemze,et al. Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases. , 2012, Blood.
[11] J. Zic,et al. A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders , 2009, Clinical Cancer Research.
[12] Angelica Selim,et al. TNM Classification System for Primary Cutaneous Lymphomas , 2008 .
[13] M. Duvic,et al. Treatment of Transformed Mycosis Fungoides with Intermittent Low-Dose Gemcitabine , 2008, Oncology.
[14] J. Merlio,et al. Common chromosomal abnormalities in mycosis fungoides transformation , 2007, Genes, chromosomes & cancer.
[15] L. Thomas,et al. Transformed mycosis fungoides: clinicopathological features and outcome , 2007, The British journal of dermatology.
[16] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Nicola Pimpinelli,et al. Defining early mycosis fungoides. , 2005, Journal of the American Academy of Dermatology.
[18] T. Petrella,et al. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas. , 2000, Blood.
[19] R. Kurzrock,et al. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. , 1998, Blood.